Hannay Michael Charles Ferguson 4

What Happened Michael Hannay, Bicycle Therapeutics' Chief Product & Supply Chain Officer, sold a total of 1,761 Bicyc­le Therapeutics (BCYC) shares in two open-market transactions to cover tax withholding on vested RSUs. On 2026-07-02 he sold 1,506 shares at a weighted average price of $4.27 for proceeds of $6,431 (prices ranged $4.26–$4.29). On 2026-07-06 he sold 255 shares at a weighted average price of $4.31 for proceeds of $1,099 (prices ranged $4.30–$4.31). Combined proceeds ≈ $7,530. These sales were reported on a Form 4 filed 2026-07-07.

Key Details

• Transaction types: Sales (open market) to satisfy tax withholding on RSU settlement (mandatory "sell-to-cover").
• Dates & prices:
  • 2026-07-02 — 1,506 shares @ weighted avg $4.27; per-footnote range $4.26–$4.29; proceeds $6,431.
  • 2026-07-06 — 255 shares @ weighted avg $4.31; per-footnote range $4.30–$4.31; proceeds $1,099.
• Total shares sold: 1,761; total proceeds ≈ $7,530.
• Shares owned after the transactions: Not specified in the information provided.
• Footnotes: F1 — sale mandated by award agreement to cover statutory tax withholding (not a discretionary sale). F2/F3 — reported prices are weighted averages with per-trade price ranges; detailed per-price breakdown available on request.
• Filing: Form 4 filed 2026-07-07 reporting both trades.

Context

• These sales were sell-to-cover transactions tied to RSU vesting; such mandated sales are common and typically do not signal a change in insider sentiment. They differ from discretionary sales (which might be more informative) and from purchases (which are often seen as a stronger bullish signal).